AstraZeneca plc (AZN - Free Report) is scheduled to report fourth-quarter and full-year 2019 results on Feb 14
The company’s earnings beat estimates in each of the past four quarters with the average surprise being 36.96%.
Shares of AstraZeneca have increased 36% in the past year compared with the industry‘s increase of 13.7%.
In the last reported quarter, AstraZeneca delivered a positive earnings surprise of 11.11%.
Factors at Play
Sales of newer medicines, mainly cancer drugs Lynparza, Tagrisso and Imfinzi are expected to have benefited the company’s top line in the fourth quarter by offsetting lower sales of many other legacy medicines.
Product sales in the third quarter benefited from favorable inventory and gross-to-net movements. However, the benefits were absent this time around.
Continued underlying demand growth and strong uptake in the first-line setting are likely to have pushed up sales of Tagrisso in the quarter.
Sales of Lynparza, which is marketed in collaboration with Merck (MRK - Free Report) , are likely to have been driven by expanded use in ovarian and breast cancer. In December, the FDA granted approval to Lynparza as a first-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer. However, this label expansion is unlikely to have contributed to the drug’s sales in the fourth quarter.
Fourth-quarter sales of Imfinzi are likely to have benefited from strong demand trends in the United States, especially in lung cancer indications.
AstraZeneca’s other major drugs like Fasenra, Brilinta and Farxiga are likely to have contributed to sales growth the soon-to-be reported quarter.
However, please note that increased competition and formulary plan changes for competitors’ drugs hurt sales of Farxiga in the United States in the third quarter. We expect these factors to have hurt sales in the fourth quarter as well.
Sales of AstraZeneca’s COPD drug Symbicort’s have been declining due to pricing pressure and competition. These factors are likely to have impacted fourth-quarter sales of the drug as well.
Sales of AstraZeneca’s major legacy drugs have been declining due to rising generic competition. The trend is likely to have continued in the fourth quarter.
On the fourth-quarter conference call, we expect management to discuss launch plans for AstraZeneca and partner Japan’s Daiichi Sankyo’s trastuzumab deruxtecan, which was approved by the FDA in metastatic breast cancer in December 2019 under the brand name, Enhertu.
Our proven model does not conclusively predict an earnings beat for AstraZeneca in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: AstraZeneca’s Earnings ESP is 0.00% as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at 53 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: AstraZeneca carries a Zacks Rank #3.
Stock to Consider
Here are two biotech stocks that have the right combination of elements to beat on earnings this time around.
Karyopharm Therapeutics Inc. (KPTI - Free Report) has an Earnings ESP of +3.05% and a Zacks Rank #3. The company is scheduled to release fourth-quarter results on Feb 27.
Nektar Therapeutics (NKTR - Free Report) has an Earnings ESP of +8.36% and a Zacks Rank #3.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>